MedWorm: Lymphoma

Effect of simplification from protease inhibitors to boosted atazanavir-based regimens in real-life conditions

HIV Medicine — Sat, 20 Mar 2010 00:00:00 +0100

Atazanavir (ATV) boosted with ritonavir (ATV/r) is a potent, well-tolerated, once-daily protease inhibitor (PI). Few data are available on this agent as a treatment simplification option for patients taking other PIs. The aim of the study was to determine the effectiveness and safety of ATV-containing regimens in patients who have simplified their antiretroviral treatment. SIMPATAZ was a multicentre, prospective, noninterventional study in patients who had undetectable HIV RNA on their current PI-containing therapy and who were switched to an ATV/r-based regimen. Patients underwent a routine physical examination, and data were collected on HIV RNA levels, CD4 cell counts, liver function, lipid parameters, adverse reactions, adherence to treatment and patient satisfaction. A total of 183 pa...

MedWorm Sponsor Message: The Lymphoma Research Foundation (LRF) is America's largest lymphoma-focused voluntary health organization devoted exclusively to funding lymphoma research and providing patients and health care professionals with critical information on the disease.

MRI Findings in Lymphomatosis Cerebri: Description of a Case and Revision of the Literature

Journal of Neuroimaging — Sat, 20 Mar 2010 00:00:00 +0100

We present our findings along with a review of the neuroradiological literature. J Neuroimaging 2010;XX:1-4. (Source: Journal of Neuroimaging)

Levact(R) (bendamustine) Recommended for Approval in Europe for Treating Blood Cancers

HSMN NewsFeed — Fri, 19 Mar 2010 17:59:03 +0100

CAMBRIDGE, England, March 19, 2010 (HSMN NewsFeed) -- Mundipharma announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending that marketing authorisatio... Biopharmaceuticals, Oncology, RegulatoryMundipharma, Levact, bendamustine, non-Hodgkin's lymphoma, leukemia, myeloma (Source: HSMN NewsFeed)

Understanding Radiation-Induced Vascular Disease⁎

Journal of the American College of Cardiology — Fri, 19 Mar 2010 14:00:31 +0100

Radiation injury of blood vessels was originally described more than a century ago and remains a contemporary clinical problem, despite dramatic advances in the field of radiation oncology (). Clinical studies indicate that patients who have previously undergone radiation therapy for various malignancies—such as lymphoma, breast cancer, and head and neck cancer—are at increased risk for developing vascular disease (). The consequences are significant; depending upon the study, the relative risk of suffering a clinical cardiovascular event (i.e., myocardial infarction, stroke) related to radiation therapy ranges from approximately 1.5- to 4.0-fold, and this risk is further amplified in the presence of traditional cardiovascular risk factors (). Most cardiovascular events occur >10 years...

Antisoma Initiates Phase IIb Trial Of AS1411 In Acute Myeloid Leukaemia

Health News from Medical News Today — Fri, 19 Mar 2010 07:00:00 +0100

Antisoma plc (LSE: ASM; USOTC: ATSMY) announces that it has started a randomised, controlled, multi-territory, phase IIb trial of AS1411 in patients with acute myeloid leukaemia (AML). Dr Ursula Ney, Chief Operating Officer of Antisoma, said: "AML is a devastating disease for which new treatment options are desperately needed. This phase IIb trial builds on earlier positive phase II findings, and is designed to pave the way for a registration trial of AS1411 in AML." The phase IIb trial is enrolling patients with AML in first relapse or refractory to one prior treatment... (Source: Health News from Medical News Today)

Antisoma Initiates Phase IIb Trial Of AS1411 In Acute Myeloid Leukaemia

Cancer / Oncology News From Medical News Today — Fri, 19 Mar 2010 07:00:00 +0100

Prevalence of Helicobacter pylori vacA, cagA, iceA and oipA genotypes in Tunisian patients

BioMed Central — Fri, 19 Mar 2010 00:00:00 +0100

Conclusion: Our results showed that in 46% (131 strains among 281), the H. pylori strains were highly virulent in relation of the three or four virulent factors they could carry. These finding were described before in the literature. Tunisian patients were colonized by one or multiple strains of H. pylori in the same time in relation of presence of vacA m1/m2 and iceA1/ iceA2 in the same biopsy. The discordance between strains isolated from antrum and fundus was high, and it is in favour of multicolonization. (Source: BioMed Central)

Marginal zone lymphomas in children and the young adult population; characterization of genetic aberrations by FISH and RT-PCR

Modern Pathology AOP — Fri, 19 Mar 2010 00:00:00 +0100

Authors: Kathryn A Rizzo, Berthold Streubel, Stefania Pittaluga, Andreas Chott, Liqiang Xi, Mark Raffeld & Elaine S Jaffe (Source: Modern Pathology AOP)

Burkitt's Lymphoma in Early Pregnancy [DIAGNOSIS IN ONCOLOGY]

Journal of Clinical Oncology — Thu, 18 Mar 2010 22:01:37 +0100

(Source: Journal of Clinical Oncology)

Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy [Hematologic Malignancies]

Journal of Clinical Oncology — Thu, 18 Mar 2010 22:01:37 +0100

Conclusion Six cycles of ABVD is an effective and safe treatment for limited-stage, nonbulky HL and would spare young patients radiation toxicity. Interim positron emission tomography/computed tomography scans in current and future trials may identify those patients who require less than six cycles of chemotherapy. (Source: Journal of Clinical Oncology)

Gene Expression Profiling Uncovers Molecular Classifiers for the Recognition of Anaplastic Large-Cell Lymphoma Within Peripheral T-Cell Neoplasms [Hematologic Malignancies]

Journal of Clinical Oncology — Thu, 18 Mar 2010 22:01:36 +0100

Conclusion We proved that experimentally controlled GEP in ALCL cell lines represents a powerful tool to identify meaningful signaling networks for the recognition of systemic primary T-NHL. The identification of a molecular signature specific for ALCL suggests that these T-NHLs may represent a unique entity discernible from other PTCLs, and that a restricted number of genes can be instrumental for clinical stratification and, possibly, therapy of T-NHL. (Source: Journal of Clinical Oncology)

Phase I Study of KW-0761, a Defucosylated Humanized Anti-CCR4 Antibody, in Relapsed Patients With Adult T-Cell Leukemia-Lymphoma and Peripheral T-Cell Lymphoma [Hematologic Malignancies]

Journal of Clinical Oncology — Thu, 18 Mar 2010 22:01:36 +0100

Conclusion KW-0761 was tolerated at all the dose levels tested, demonstrating potential efficacy against relapsed CCR4-positive ATL or PTCL. Subsequent phase II studies at the 1.0 mg/kg dose are thus warranted. (Source: Journal of Clinical Oncology)

Families Facing Cancer: Coping with the problems and possibilities together

Psychology Today Relationships Center — Thu, 18 Mar 2010 16:21:24 +0100

It is still dark with just a hint of light in the Eastern sky. But the full moon gives the snow cover in our back yard a ghostly glow. I have the gift of a quiet Sunday morning at home to write to you and introduce myself and my family.Before May, 2005, we were a relatively normal family, very close and mostly happy. We were immersed in planning our lives. Then, on May 1, I woke up with a searing pain in my shoulder. Within a week I was hospitalized with extremely advanced Stage 4, Non-Hodgkins Lymphoma. I was given less than a 25 percent chance of surviving. Our family's comfortable world was shattered. The challenges were overwhelming for each of us separately and for us as a family. How would we come together and encourage each other, while simultaneously needing so much support ourselv...

Detection of cryptic and variant IGH-MYC rearrangements in high-grade non-Hodgkin's lymphoma by fluorescence in situ hybridization: implications for cytogenetic testing

Cancer Genetics and Cytogenetics — Thu, 18 Mar 2010 16:03:07 +0100

We describe three cases of high-grade lymphoma in which cryptic insertion events, resulting in clinically significant IGH-MYC rearrangements, were detectable using an IGH/MYC three-color, dual-fusion fluorescence in situ hybridization (FISH) probe set, but were not detected using break-apart MYC FISH probes, thus highlighting the limitations of using break-apart probes as a stand-alone test, particularly with the increased use of interphase FISH analysis of formalin-fixed, paraffin-embedded tissue sections in the diagnostic work-up of these patients. (Source: Cancer Genetics and Cytogenetics)

Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma

Cancer Genetics and Cytogenetics — Thu, 18 Mar 2010 16:03:06 +0100

This study suggests that GSTT1 deletion may significantly increase the risk of drug-related toxicity after R-CHOP chemotherapy in patients with DLBCL, and is associated with worse prognosis in males. (Source: Cancer Genetics and Cytogenetics)

The t(14;18)(q32;q21)/IGH-MALT1 translocation in MALT lymphomas contains templated nucleotide insertions and a major breakpoint region similar to follicular and mantle cell lymphoma

Blood — Thu, 18 Mar 2010 16:02:03 +0100

The t(14;18)(q32;q21) involving the immunoglobulin heavy chain locus (IGH) and the MALT1 gene is a recurrent abnormality in mucosa-associated lymphoid tissue (MALT) lymphomas. However, the nucleotide sequence of only one t(14;18)–positive MALT lymphoma has been reported so far. We here report the molecular characterization of the IGH-MALT1 fusion products in 5 new cases of t(14;18)–positive MALT lymphomas. Similar to the IGH-associated translocations in follicular and mantle cell lymphomas, the IGH-MALT1 junctions in MALT lymphoma showed all features of a recombination signal sequence–guided V(D)J-mediated translocation at the IGH locus. Furthermore, analogous to follicular and mantle cell lymphoma, templated nucleotides (T-nucleotides) were identified at the t(14;18)/IGH...

Coexisting follicular and mantle cell lymphoma with each having an in situ component: a novel, curious, and complex consultation case of coincidental, composite, colonizing lymphoma.

American Journal of Clinical Pathology — Thu, 18 Mar 2010 15:40:32 +0100

We present a case of a spleen revealing histologic features of follicular lymphoma, without any indication of a second lymphoma. Immunohistochemical stains supported this diagnosis and showed the follicular lymphoma to be BCL2-. However, these studies revealed 2 additional unexpected findings: cyclin D1+ mantle zone cells surrounding neoplastic and reactive follicles (indicative of in situ mantle cell lymphoma) and BCL2-bright, histologically nonneoplastic follicles (indicative of in situ follicular lymphoma). ImmunoFISH and microdissection and polymerase chain reaction analysis documented the clonal nature of the cyclin D1+ mantle zones and illustrated clonal independence from the follicular lymphoma. This case illustrates an uncommon and unusual composite follicular and mantle cell lymph...

Minimal residual disease detection by flow cytometry in adult T-cell leukemia/lymphoma.

American Journal of Clinical Pathology — Thu, 18 Mar 2010 15:40:28 +0100

Authors: Shao H, Yuan CM, Xi L, Raffeld M, Morris JC, Janik JE, Stetler-Stevenson M Little information exists regarding the detection of minimal residual disease (MRD) in adult T-cell leukemia/lymphoma (ATLL). We evaluated 75 peripheral blood samples from 17 ATLL cases using flow cytometry (FC); 50 of the samples were concurrently evaluated by polymerase chain reaction (PCR) for clonal T-cell receptor gamma chain (TRG) gene rearrangement and the presence of human T-cell lymphotropic virus-1 proviral sequences. Residual ATLL cells were identified using a multiparametric approach to identify aberrant T-cell immunophenotypes. Malignant T cells were CD4+, CD3 dim+, CD26-, CD25 bright, CD7+, and CD27+, with occasional dim expression of CD2 or CD5. FC exhibited a high sensitivity, detecting ...

How cells protect themselves from cancer

ScienceDaily Headlines — Thu, 18 Mar 2010 15:00:00 +0100

Cells have two different protection programs to safeguard them from getting out of control under stress and from dividing without stopping and developing cancer. Now for the first time, using an animal model for lymphoma, cancer researchers have shown that these two protection programs work together through an interaction with normal immune cells to prevent tumors. Their findings may be of fundamental importance in the fight against cancer. (Source: ScienceDaily Headlines)

Single-shot Zevalin presents new lymphoma Rx option

Cancer Network — Thu, 18 Mar 2010 12:00:00 +0100

Unlike conventional radiation, Yttrium-90-ibritumomab tiuxetan (Zevalin) induces cellular damage only in the targeted tumor cells and has demonstrated activity in follicular and diffuse large B-cell non-Hodgkin’s lymphoma. (Source: Cancer Network)

Follicular lymphoma: Is watchful waiting still a treatment option in era of new and improved therapy?

Cancer Network — Thu, 18 Mar 2010 12:00:00 +0100

In asymptomatic disease, overall survival is often the same with immediate treatment vs watch and wait. The deciding factor may be what patients are willing to tolerate. (Source: Cancer Network)

Blocking Cancer In Its Path: New Cellular Defect Discovered

Health News from Medical News Today — Thu, 18 Mar 2010 07:00:00 +0100

UCSF researchers have discovered that a key cellular defect that disturbs the production of proteins in human cells can lead to cancer susceptibility. The scientists also found that a new generation of inhibitory drugs offers promise in correcting this defect. According to the study team, this discovery has broad clinical implications in the fight against cancer and could affect treatment of lymphoma and many other forms of the disease, including prostate cancer, breast cancer, colorectal cancer, brain cancer and multiple myeloma... (Source: Health News from Medical News Today)

Higher expression levels of activation-induced cytidine deaminase distinguish hairy cell leukemia from hairy cell leukemia-variant and splenic marginal zone lymphoma

Leukemia — Thu, 18 Mar 2010 00:00:00 +0100

Authors: S L Hockley, A Morilla, M Else, C Dearden, D Catovsky, G J Morgan, E Matutes & D Gonzalez (Source: Leukemia)

Normoglycemic plasma glucose levels affect F-18 FDG uptake in the brain

Annals of Nuclear Medicine — Wed, 17 Mar 2010 15:52:04 +0100

Conclusions Our results indicated that plasma glucose levels that are within the normoglycemic range have a small but systematic effect on F-18 FDG uptake in the brain (following an inverse relationship). Normalizing plasma glucose levels to a standard glucose concentration successfully reduced the intra-subject variability of SUV measures. Inter-subject variability, however, remained high suggesting that other factors have an influence as well. Content Type Journal ArticleCategory Short CommunicationDOI 10.1007/s12149-010-0359-9Authors Jonas Claeys, Ghent University Hospital Department of Nuclear Medicine De Pintelaan 185 9000 Ghent BelgiumKoen Mertens, Ghent University Hospital Department of Nuclear Medicine De Pintelaan 185 9000 Ghent BelgiumYves D’Asseler, Gh...

Rheumatoid arthritis, treatment with corticosteroids and risk of malignant lymphomas: results from a case-control study

Annals of the Rheumatic Diseases — Wed, 17 Mar 2010 14:45:57 +0100

Conclusion In this RA population, use of steroids was associated with reduced lymphoma risk. Whether this association is a generic effect of steroids or specific to the studied population remains unknown. (Source: Annals of the Rheumatic Diseases)

How Cells Protect Themselves From Cancer

Biology / Biochemistry News From Medical News Today — Wed, 17 Mar 2010 13:00:00 +0100

How Cells Protect Themselves From Cancer

Health News from Medical News Today — Wed, 17 Mar 2010 13:00:00 +0100

Cells have two different protection programs to safeguard them from getting out of control under stress and from dividing without stopping and developing cancer. Until now, researchers assumed that these protective systems were prompted separately from each other. Now for the first time, using an animal model for lymphoma, cancer researchers of the Max Delbruck Center (MDC) Berlin-Buch and the Charite - University Hospital Berlin in Germany have shown that these two protection programs work together through an interaction with normal immune cells to prevent tumors. The findings of Dr... (Source: Health News from Medical News Today)

Simultaneous Cytomorphologic and Multiparametric Flow Cytometric Analysis on Lymph Node Samples Is Faster Than and as Valid as Histopathologic Study to Diagnose Most Non-Hodgkin Lymphomas

Medscape Today Headlines — Wed, 17 Mar 2010 11:04:30 +0100

How does simultaneous cytomorphologic and multiparametric flow cytometric analysis on lymph nodes measure up to histopathologic analysis for diagnosing non-Hodgkin lymphomas? American Journal of Clinical Pathology (Source: Medscape Today Headlines)

Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide regimen in elderly patients with recurrent mantle cell lymphoma

Cancer — Wed, 17 Mar 2010 00:00:00 +0100

Targeting the tumor microenvironment and angiogenesis is a novel lymphoma therapeutic strategy. The authors report safety, activity, and angiogenic profiling results with the rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide (RT-PEPC) regimen in patients with recurrent mantle cell lymphoma (MCL).RT-PEPC included induction (Months 1-3) of rituximab 4 times weekly, daily thalidomide (50 mg), and PEPC followed by maintenance thalidomide (100 mg), oral PEPC titrated to the neutrophil count, and rituximab every 4 months. Endpoints included safety, efficacy, quality of life (QoL), and translational studies, including tumor angiogenic phenotyping, plasma vascular endothelial growth factor (VEGF), and circulating endothelial cells.Twenty-five patients were en...

Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma

Hematological Oncology — Wed, 17 Mar 2010 00:00:00 +0100

The R-CHOP regimen has been found to improve the outcome of diffuse large B-cell lymphoma (DLBCL). However, it does not provide a satisfactory treatment outcome in the high-risk group. We previously administered the CyclOBEAP regimen to patients with DLBCL, and reported its safety and efficacy. The R-CyclOBEAP regimen was administered over a total period of 12 weeks, and rituximab 375 mg/m2 was given every 2 weeks. There were 101 eligible patients. CR was achieved in 96 patients (95%). The 5-year overall survival (OS) rate was 85% and progression-free survival (PFS) rate was 76%. When the patients were divided according to the IPI, the 5-year OS and PFS rates did not significantly differ among the risk groups. The 5-year PFS of the germinal centre B-cell group was 80% and that of the non-G...

Synchronous Mantle Cell Lymphoma, Chronic Lymphocytic Leukaemia and Melanoma in a Single Lymph Node.

Acta Haematologica — Wed, 17 Mar 2010 00:00:00 +0100

Authors: Addada J, Anoop P, Swansbury JG, Wotherspoon A, Thomas JM, Matutes E PMID: 20234130 [PubMed - as supplied by publisher] (Source: Acta Haematologica)

Successful treatment with intravenous immunoglobulin of severe thrombocytopenia complicated in primary Sjögren’s syndrome

Rheumatology International — Tue, 16 Mar 2010 14:49:02 +0100

We report here a rare case of patient with primary SS who developed pancytopenia with severe thrombocytopenia as an initial manifestation and successfully treated with IV immunoglobulin (IVIG). The present case suggests that pancytopenia with severe thrombocytopenia can be a difficult-to-treat abnormality, and initial manifestation of primary SS and IVIG might be an effective treatment for severe thrombocytopenia refractory to high-dose steroid in primary SS. Content Type Journal ArticleCategory Case ReportDOI 10.1007/s00296-010-1395-4Authors Bum-Su Choung, Chonbuk National University Medical School and Research Institute of Clinical Medicine Division of Rheumatology, Department of Internal Medicine San 2-20 Geumam-dong, Deokjin-gu, Jeonju Jeonbuk 561-756 South KoreaWan-Hee Yoo, ...

Cancer Stem Cells [Book and Media Reviews]

JAMA — Tue, 16 Mar 2010 13:50:41 +0100

(Source: JAMA)

New Technique Improves Accuracy Of Staging Lung Cancer

Health News from Medical News Today — Tue, 16 Mar 2010 09:00:00 +0100

A new technique being used by thoracic surgeons at Rush University Medical Center offers a more precise, less invasive and more versatile way of assessing a patient's lymph nodes and chest tumors to determine if lung cancer has spread to other parts of the body. The procedure is called endobronchial ultrasound or EBUS, and Rush is the first hospital in Illinois offering the minimally invasive system to diagnose lung cancer, lymphomas, infections and other diseases causing enlarged lymph nodes and tumors in the chest... (Source: Health News from Medical News Today)

Macrophage chemotactic protein-1 mRNA levels in non-Hodgkin lymphoma

Clinical and Experimental Medicine — Tue, 16 Mar 2010 08:50:18 +0100

Abstract Non-Hodgkin lymphoma (NHL) is one of the most common malignancies whose incidence increases, and the treatment results are not satisfactory. The aim of this study was to determine the capacity of NHL to produce MCP-1, chemokine that induces chemotaxis of macrophages and lymphoid cells. The mRNA expression and protein MCP-1 expression were determined in the samples of 20 patients with NHL and 8 reactive tonsils. MCP-1 mRNA was detected in 8/8 tonsils and in 19/20 patients with NHL by real-time PCR analysis. In addition, the amount of detected MCP-1 cDNA was significantly higher in patients with limited stage, good IPI, normal level of fibrinogen and LDH. Finally, in patients with aggressive NHL, the level of MCP-1 cDNA was higher than in indolent tumours. Immunohis...

In Cancer Fight, Teenagers Don’t Fit In

NYT > Health — Tue, 16 Mar 2010 04:30:24 +0100

Experts see a gap in treatment between pediatric and adult care. (Source: NYT > Health)

2 at 1 stroke -- how cells protect themselves from cancer

EurekAlert! - Medicine and Health — Tue, 16 Mar 2010 04:00:00 +0100

(Helmholtz Association of German Research Centres) Cells have two different protection programs to safeguard them from getting out of control under stress and from dividing without stopping and developing cancer. Now for the first time, using an animal model for lymphoma, cancer researchers in Berlin, Germany, have shown that these two protection programs work together through an interaction with normal immune cells to prevent tumors. Their findings may be of fundamental importance in the fight against cancer. (Source: EurekAlert! - Medicine and Health)

Retraction: A novel combination of Chinese medicines to treat advanced cancers and lymphomas tested in rats

Chinese Medicine — Tue, 16 Mar 2010 00:00:00 +0100

The author has withdrawn this article [1] from the public domain because they did not have permission to use the data that was presented within. In the light of this situation, BioMed Central regrets that this article is no longer available. The author apologises to all parties for the inconvenience. (Source: Chinese Medicine)

Fertility preservation after chemotherapy for Hodgkin lymphoma

Hematological Oncology — Tue, 16 Mar 2010 00:00:00 +0100

Treatment for Hodgkin lymphoma can negatively affect fertility. This review summarizes data on fertility after chemotherapy in adult patients. Alkylating chemotherapy, especially if containing procarbazine and/or cyclophosphamide, is most harmful to gonadal functioning. Alkylating regimens cause prolonged azoospermia in 90-100% of men and ovarian failure in 5-25% of women under the age of 30. Non-alkylating chemotherapy, like ABVD, is much less harmful: one-third of male patients develop transient azoospermia, and almost no female patients experience ovarian failure. Age is an important factor for women: females over 30 years have a much higher risk of acute ovarian failure. However, with long-term follow-up the cumulative risk of menopause before the age of 40 becomes the same irrespectiv...

Interleukin-2 induces NF-[kappa]B activation through BCL10 and affects its subcellular localization in natural killer lymphoma cells

The Journal of Pathology — Tue, 16 Mar 2010 00:00:00 +0100

Deregulation of nuclear factor (NF)-[kappa]B signalling is common in cancers and is essential for tumourigenesis. Constitutive NF-[kappa]B activation in extranodal natural killer (NK)-cell lymphoma, nasal type (ENKL) is known to be associated with aberrant nuclear translocation of BCL10. Here we investigated the mechanisms leading to NF-[kappa]B activation and BCL10 nuclear localization in ENKLs. Given that ENKLs are dependent on T-cell-derived interleukin-2 (IL2) for cytotoxicity and proliferation, we investigated whether IL2 modulates NF-[kappa]B activation and BCL10 subcellular localization in ENKLs. In the present study, IL2-activated NK lymphoma cells were found to induce NF-[kappa]B activation via the PI3K/Akt pathway, leading to an increase in the entry of G2/M phase and concomitant...

GB virus C infection and non-Hodgkin lymphoma: important to know but the jury is out

International Journal of Cancer — Tue, 16 Mar 2010 00:00:00 +0100

No abstract. (Source: International Journal of Cancer)

2010 Mantle Cell Lymphoma Correlative Clinical Studies Grant

ScanGrants feed — Tue, 16 Mar 2010 00:00:00 +0100

* $100K per year for 2 years: The Lymphoma Research Foundation (LRF) Mantle Cell Lymphoma Consortium seeks proposals for correlative clinical studies in mantle cell lymphoma. Applications to this initiative must be an adjunct to a major MCL research project and work in the clinical setting or with primary MCL patient samples. Innovative research by definition may uncover new questions and new areas requiring investigation. Basic funding often does not allow for additional, correlative studies to explore these areas. The intention of the current request for proposals is to fund such adjunct studies to complement and synergize with ongoing MCL trials within the NCI Cancer Cooperative Groups and/or the LRF-funded clinical projects. The applications should clearly focus on MCL and have a hi...

2010 Mantle Cell Lymphoma Project Planning Grant

ScanGrants feed — Tue, 16 Mar 2010 00:00:00 +0100

$25K for up to 2 years: The Lymphoma Research Foundation's Mantle Cell Lymphoma Consortium is seeking applications for project planning grants geared toward obtaining larger-scale research support from NIH/NCI (or another major funder). The purpose of these grants is to provide funds for MCL Consortium members and other MCL researchers to develop larger, longer-term proposals that are likely to become successfully funded from other sources, including Program Project Grants such as the POI. Multi-invenstigator, multi-site and/or mulit-disciplinary proposals are particularly encouraged. ELIGIBILITY:All principal investigators holding an academic faculty appointment, at non-profit organizations, or public or private institutions such as universities, colleges, hospitals, and laboratories, m...

High risk of azoospermia in men treated for childhood cancer

International Journal of Andrology — Tue, 16 Mar 2010 00:00:00 +0100

Childhood cancer survivors (CCS) have an increased risk of impaired spermatogenesis, but data regarding the disease- and treatment-related risk factors of azoospermia are scarce. Such information is crucial both for counselling CCS and for selecting patients for testicular tissue cryopreservation. The proportion of azoospermic men in CCS was 18% [95% confidence interval (CI): 12[ndash]26], specifically for leukaemias (19%; 95% CI: 5.5[ndash]42), Hodgkin's disease (53%; 95% CI: 29[ndash]76), non-Hodgkin's lymphoma (11%; 95% CI: 0.28[ndash]48) and testicular cancer (11%; 95% CI: 0.28[ndash]48). In CCS treated with high doses of alkylating agents, the proportion of azoospermic men was 80% (95% CI: 28[ndash]99) and if radiotherapy was used additionally, the proportion was 64% (95% CI: 35[ndash...

BCL6 Canalizes Notch-Dependent Transcription, Excluding Mastermind-like1 from Selected Target Genes during Left-Right Patterning.

Developmental Cell — Tue, 16 Mar 2010 00:00:00 +0100

Authors: Sakano D, Kato A, Parikh N, McKnight K, Terry D, Stefanovic B, Kato Y Although the Notch signaling pathway is one of the most intensely studied intracellular signaling pathways, the mechanisms by which Notch signaling regulates transcription remain incompletely understood. Here, we report that B cell leukemia/lymphoma 6 (BCL6), a transcriptional repressor, is a Notch-associated factor. BCL6 is necessary to maintain the expression of Pitx2 in the left lateral plate mesoderm during the patterning of left-right asymmetry in Xenopus embryos. For this process, BCL6 forms a complex with BCL6 corepressor (BCoR) on the promoters of selected Notch target genes such as enhancer of split related 1. BCL6 also inhibits the transcription of these genes by competing for the Notch1 intracellu...

Viral Response to Chemotherapy in Endemic Burkitt Lymphoma.

Cell Research — Tue, 16 Mar 2010 00:00:00 +0100

CONCLUSION: Cyclophosphamide may induce the lytic phase of EBV infection and is fairly effective in diminishing EBER-expressing tumor cells within 5 days. These findings provide the rationale for a trial testing synergistic tumor cell killing using cyclophosphamide with a drug like ganciclovir targeting lytically infected cells. Clin Cancer Res; 16(7); OF1-10. PMID: 20233888 [PubMed - as supplied by publisher] (Source: Cell Research)

In vitro and In vivo Selective Antitumor Activity of Edelfosine against Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Involving Lipid Rafts.

Cell Research — Tue, 16 Mar 2010 00:00:00 +0100

CONCLUSIONS: Our data indicate that edelfosine accumulates and kills MCL and CLL cells in a rather selective way, and set coclustering of Fas/CD95 and lipid rafts as a new framework in MCL and CLL therapy. Our data support a selective antitumor action of edelfosine. Clin Cancer Res; 16(7); OF1-9. PMID: 20233887 [PubMed - as supplied by publisher] (Source: Cell Research)

Transcriptional Profiles Predict Disease Outcome in Patients with Cutaneous T-Cell Lymphoma.

Cell Research — Tue, 16 Mar 2010 00:00:00 +0100

CONCLUSION: This work suggests that it may be possible to stratify CTCL patients into low-risk, intermediate-risk, and high-risk groups based on gene expression. Clin Cancer Res; 16(7); OF1-9. PMID: 20233883 [PubMed - as supplied by publisher] (Source: Cell Research)

Increased Risk of Second Primary Cancers After a Diagnosis of Melanoma [Study]

Archives of Dermatology — Mon, 15 Mar 2010 19:50:57 +0100

Conclusions Melanoma survivors have an approximately 9-fold increased risk of developing subsequent melanoma compared with the general population. The risk remains elevated more than 20 years after the initial melanoma diagnosis. This increased risk may be owing to behavioral factors, genetic susceptibility, or medical surveillance. Although the percentage of subsequent primary melanomas thicker than 1 mm is lower than for the first of multiple primary melanomas, it is still substantial. Melanoma survivors should remain under surveillance not only for recurrence but also for future primary melanomas and other cancers. (Source: Archives of Dermatology)

A case–control study of tobacco use and other non-occupational risk factors for lymphoma subtypes defined by t(14; 18) translocations and bcl-2 expression

Cancer Causes and Control — Mon, 15 Mar 2010 17:57:58 +0100

Conclusions The association between t(14; 18)-negative NHL and cigarette smoking was unexpected given previous evidence of associations between smoking and follicular lymphoma (which is largely t(14; 18)-positive). Future studies characterizing additional molecular characteristics of t(14; 18)-negative NHL may help determine whether the association with smoking may have been causal versus an artifact of chance or bias. Content Type Journal ArticleCategory Brief reportDOI 10.1007/s10552-010-9531-8Authors Cindy M. Chang, National Cancer Institute Infections and Immunoepidemiology Branch Rockville MD USAJane C. Schroeder, University of North Carolina at Chapel Hill Department of Epidemiology, School of Public Health Chapel Hill NC USAAndrew F. Olshan, University of Nor...

FORMA teams to develop lymphoma drugs

bizjournals.com Health Care:Biotechnology headlines — Mon, 15 Mar 2010 17:56:49 +0100

The Leukemia & Lymphoma Society and FORMA Therapeutics Inc. have partnered to develop drug candidates targeting lymphoma. (Source: bizjournals.com Health Care:Biotechnology headlines)

Lymphoma endothelium preferentially expresses Tim-3 and facilitates the progression of lymphoma by mediating immune evasion

The Journal of Experimental Medicine — Mon, 15 Mar 2010 17:12:56 +0100

We report a previously unrecognized mechanism by which lymphoma endothelium facilitates the growth and dissemination of lymphoma by interacting with circulated T cells and suppresses the activation of CD4+ T cells. Global gene expression profiles of microdissected endothelium from lymphoma and reactive lymph nodes revealed that T cell immunoglobulin and mucin domain–containing molecule 3 (Tim-3) was preferentially expressed in lymphoma-derived endothelial cells (ECs). Clinically, the level of Tim-3 in B cell lymphoma endothelium was closely correlated to both dissemination and poor prognosis. In vitro, Tim-3+ ECs modulated T cell response to lymphoma surrogate antigens by suppressing activation of CD4+ T lymphocytes through the activation of the interleukin-6–STAT3 pathway, inh...

Kids, Adolescents, and Young Adults Cancer Study—A Methodologic Approach in Cancer Epidemiology Research

Journal of Cancer Epidemiology — Mon, 15 Mar 2010 16:18:44 +0100

Advances have been made in treatment and outcomes for pediatric cancer. However adolescents and young adults (AYAs) with cancer have not experienced similar relative improvements. We undertook a study to develop the methodology necessary for epidemiologic cancer research in these age groups. Our goal was to create the Kids, Adolescents, and Young Adults Cancer (KAYAC) project to create a resource to address research questions relevant to this population. We used a combination of clinic and population-based ascertainment to enroll 111 cases aged 0–39 for this methodology development study. The largest groups of cancer types enrolled include: breast cancer, leukemia, lymphoma, and melanoma. The overall participation rate is 69.8% and varies by age and tumor type. The study included...

8p11 myeloproliferative syndrome: a review

Human Pathology — Mon, 15 Mar 2010 15:18:06 +0100

Summary: The 8p11 myeloproliferative syndrome is an aggressive neoplasm associated with chromosomal translocations involving the fibroblast growth factor receptor 1 tyrosine kinase gene on chromosome 8p11-12. By our count, 65 cases are currently reported in the literature. This neoplasm affects patients of all ages, with a slight male predominance. Patients often present with peripheral blood eosinophilia without basophilia. Bone marrow examination commonly is hypercellular, with or without eosinophilia, which usually leads to the initial diagnosis of a myeloproliferative neoplasm. Many patients also present with or develop lymphadenopathy. Lymph node biopsy in these patients has commonly shown lymphoblastic leukemia/lymphoma, most often reported as being of T-cell lineage, but bilineal my...

Risk Stratification Imperative To Treatment Selection In Patients With AML

Lymphoma / Leukemia News From Medical News Today — Mon, 15 Mar 2010 11:00:00 +0100

Risk Stratification Imperative To Treatment Selection In Patients With AML

Health News from Medical News Today — Mon, 15 Mar 2010 11:00:00 +0100

Using risk stratification to assist in treatment selection was just one of the focal points at a recent presentation of the NCCN Clinical Practice Guidelines for Oncology (NCCN Guidelines™) for Acute Myeloid Leukemia (AML) at the NCCN 15th Annual Conference. B. Douglas Smith, MD of The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and a member of the NCCN Guidelines Panel for AML, spoke about the challenges in treating AML as well as recent updates to the NCCN Guidelines™. Dr... (Source: Health News from Medical News Today)

A Functional Polymorphism in the NAD(P)H Oxidase Subunit CYBA Is Related to Gene Expression, Enzyme Activity, and Outcome in Non-Hodgkin Lymphoma

Cancer Research — Mon, 15 Mar 2010 04:07:29 +0100

A genetic variant in NAD(P)H oxidase confers a lower activity in formation of reactive oxygen species (ROS) and may exhibit reduced susceptibility to chemotherapies that act through ROS generation. (Source: Cancer Research)

MiRNA profiling in B non-Hodgkin lymphoma: a MYC-related miRNA profile characterizes Burkitt lymphoma

British Journal of Haematology — Mon, 15 Mar 2010 00:00:00 +0100

(Source: British Journal of Haematology)

The use of synchrotron infrared microspectroscopy in the assessment of cutaneous T-cell lymphoma vs. pityriasis lichenoides chronica

Photodermatology, Photoimmunology and Photomedicine — Mon, 15 Mar 2010 00:00:00 +0100

This study was performed on 20 patients with a mean age of 50 years. They were divided into two groups: mycosis fungoides (MF) (stage IA, IB and IIA) and pityriasis lichenoides chronica (PLC). Immunophenotyping using antibodies CD3, CD4, CD8, CD20 and CD30 was performed. Synchrotron Fourier transform infrared microspectroscopy (S-FTIRM) was performed on cell nuclei to assess chemical differences between MF and PLC cases as a potential complementary screening tool. Dermal spectra of both MF and PLC were compared using principal components analysis (PCA) of the S-FTIRM data. All PLC spectra was clustered together. However, the MF spectra formed two clusters, one that grouped with the PLC and the other grouped separately. Moreover, protein and nucleic acids showed highly significant differenc...

The role of chromosome 21 in hematology and oncology

Genes, Chromosomes and Cancer — Mon, 15 Mar 2010 00:00:00 +0100

Newborns and children with Down syndrome (DS) often present with congenital transient leukemia and have an increased risk of acute myeloid leukemia and acute lymphoblastic leukemia. Thus, constitutional trisomy 21 represents an excellent model to study the origin and progression of leukemia. However, trisomy 21 can also occur as a somatic chromosome aberration leading to sporadic leukemia. During the 50 years, since the discovery of constitutional trisomy 21 in DS, we have also learned that this small chromosome 21, harboring about 300 genes, may be involved in numerous structural aberrations, e.g., translocations, deletions, and amplifications, in leukemias, lymphomas, and solid tumors. Moreover, genes located on chromosome 21 have been identified that play an important role in tumorigene...

Review: Primary Central Nervous System Lymphoma

NeLM - News — Mon, 15 Mar 2010 00:00:00 +0100

Source: Archives of Neurology Area: News Primary central nervous system (CNS) lymphoma (PCNSL), is an uncommon variant of extra-nodal non-Hodgkin lymphoma (NHL), can affect any part of the neuraxis including the eyes, brain, leptomeninges, or spinal cord. This review, published in the Archives of Neurology, discusses: . The clinical features of the condition . Diagnostic evaluation . Treatment, including corticosteroids, combined-modality therapy, chemotherapy, intrathecal chemotherapy, high-dose chemotherapy with stem-cell rescue, and salvage therapy . Neurotoxic effects of the condition, as well as due to the results of the treatment strategies. (Source: NeLM - News)

FT-IR, Raman, RRS measurements and DFT calculation for doxorubicin

Microscopy Research and Technique — Mon, 15 Mar 2010 00:00:00 +0100

Doxorubicin (DOXO) is a powerful anthracycline antibiotic used to treat many human neoplasms, including acute leukemias, lymphomas, stomach, breast and ovarian cancer, and bone tumors, yet causing cardiotoxicity at the same time. For this reason, there is a great interest in medical field to gain deep insight and knowledge of this molecule. Raman, Fourier Transform Infrared (FT-IR) absorption spectroscopy, and Resonance Raman scattering were performed for the vibrational characterization of DOXO molecule. Density function theorem (DFT) modeling of Raman and FT-IR spectra were used for the assignment of the vibrational frequencies. The optimized molecular structured was obtained, first, on the basis of potential energy distribution. The simulation for vibrational bands is based on the calcu...

Thalidomide for the Control of Severe Paraneoplastic Pruritus Associated With Hodgkin's Disease.

The American Journal of Hospice and Palliative Care — Mon, 15 Mar 2010 00:00:00 +0100

Authors: Gonçalves F A 22-year-old woman with nodular sclerosis type II Hodgkin lymphoma diagnosed in June 2001. She initially underwent chemotherapy with 6 cycles of ABVD (adriamycin, bleomycin, vincristine, dacarbazine) regimen, leading to clinical remission. As it relapsed, she was again treated with 2 different chemotherapy regimens. In November 2003, she underwent bone marrow autotransplantation, but it relapsed after 2 months. After that, she was treated with chemotherapy in monotherapy until November 2005. In December 2005, she was referred to palliative care. Her main symptom was very severe pruritus that interfered with all aspects of her life, making her scratch continuously and interfering in all aspects of her life. She was treated with loratadine, hydroxyzine, prednis...

Effect of addition of rituximab to salvage chemotherapy on outcome of patients with diffuse large B-cell lymphoma relapsing after an autologous stem-cell transplantation.

Ann Oncol — Mon, 15 Mar 2010 00:00:00 +0100

CONCLUSIONS: The addition of rituximab to salvage chemotherapy improves response rates and EFS in patients with relapsed DLBCL after ASCT. These patients may benefit from rituximab retreatment, although larger prospective studies are needed to confirm these results. PMID: 20231299 [PubMed - as supplied by publisher] (Source: Ann Oncol)

Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma.

Ann Oncol — Mon, 15 Mar 2010 00:00:00 +0100

CONCLUSIONS: For CD5+ DLBCL, the addition of rituximab to chemotherapy significantly improved the PFS, but not OS. Therefore, it is thought that a new treatment strategy is necessary for CD5+ DLBCL. PMID: 20231297 [PubMed - as supplied by publisher] (Source: Ann Oncol)

Biological and clinical significance of GSK-3beta in mantle cell lymphoma-an immunohistochemical study.

International Journal of Clinical and Experimental Pathology — Sun, 14 Mar 2010 20:24:03 +0100

Authors: Chung R, Peters AC, Armanious H, Anand M, Gelebart P, Lai R GSK-3beta, a biologically important signalling protein, is regulated by the Wnt canonical and the PI3K/Akt pathways. We recently reported that mantle cell lymphoma (MCL) frequently shows evidence of GSK-3beta inactivation, since GSK-3beta is phoshorylated at its functionally critical serine 9 residue in all MCL cell lines and the majority of MCL tumors examined. To further assess the clinical and biological significance of GSK-3beta inactivation in MCL, we employed immunohistochemistry to assess the expression of the phosphorylated/inactive form of GSK-3beta (pGSK-3beta) in 83 paraffin-embedded tumors, and correlated its expression with various biological and clinical parameters. Dichotomizing pGSK-3beta into 2 groups...

Hormonal and Sex Impact on the Epidemiology of Canine Lymphoma

Journal of Cancer Epidemiology — Sun, 14 Mar 2010 15:51:09 +0100

This study examines the influence of sex on lymphoma risk in a relevant large animal model. Records for dogs in the Veterinary Medical Database were analyzed from 1964 to 2002. Risk ratios were calculated to evaluate associations between sex, neutering status, and lymphoma occurrence. A total of 14,573 cases and 1,157,342 controls were identified. Intact females had a significantly lower risk of developing lymphoma, Odds Ratio 0.69 (0.63–0.74) with a P<.001. We conclude that there is a sex effect on NHL risk in dogs similar to humans. We hypothesize that the hormone levels of intact females lower the risk of NHL. The possibility of a protective role of endogenous estrogens in the etiology of NHL should be investigated. (Source: Journal of Cancer Epidemiology)

BioSante Announces Positive Leukemia Vaccine Results

Health News from Medical News Today — Sun, 14 Mar 2010 07:00:00 +0100

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) announced positive results of a human clinical study that show that its GVAX Leukemia vaccine may be able to reduce or eliminate the last remaining cancer cells in some chronic myeloid leukemia (CML) patients taking the drug Gleevec (imatinib mesylate). All patients enrolled in the trial used Gleevec for at least one year and still had cancer cells present. The study was conducted by researchers at the Johns Hopkins Kimmel Cancer Center in Baltimore, Maryland, led by Hyam Levitsky, M.D... (Source: Health News from Medical News Today)

BioSante Announces Positive Leukemia Vaccine Results

Immune System / Vaccines News From Medical News Today — Sun, 14 Mar 2010 07:00:00 +0100

Current Approaches to the Management of Pediatric Hodgkin Lymphoma

Pediatric Drugs — Sat, 13 Mar 2010 15:06:38 +0100

(Source: Pediatric Drugs)

Celiac disease in Brazilian patients: associations, complications and causes of death. Forty years of clinical experience

Arquivos de Gastroenterologia — Sat, 13 Mar 2010 14:23:58 +0100

Conclusions - This experience is similar to those described in the world literature. Celiac disease presents the same characteristics independently of the geographic region. We recommend periodic evaluations, from childhood, independent of the duration of the diet. The key is to establish an interval between evaluations.CONTEXTO: A doença celíaca é uma enfermidade multissistêmica e autoimune que pode se manifestar em qualquer idade, em indivíduos geneticamente predispostos. OBJETIVO: Identificação das associações, complicações e causas de morte em pacientes brasileiros após longo período de acompanhamento. MÉTODOS: Foram estudados retrospectivamente 157 pacientes, 23 adolescentes e 134 adultos, 79,6% do sexo feminino e 20,4% do masculino, 75,8% ao diagnóstico e 24,2% em diet...

FDA Approves Five-Day Dosing Regimen For Dacogen(R) (decitabine) For Injection, Offering A New Outpatient Dosing Option For Myelodysplastic Syndromes

Health News from Medical News Today — Sat, 13 Mar 2010 09:00:00 +0100

Eisai Inc announced that the U.S. Food and Drug Administration (FDA) has approved a five-day dosing regimen for Dacogen® (decitabine) for Injection to treat patients with myelodysplastic syndromes (MDS), a group of bone marrow diseases that alter the production of functional blood cells. The new outpatient dosing option provides physicians and patients with the flexibility of a dosing regimen with a reduced infusion time. Dacogen is the only hypomethylating agent approved for a five-day dosing regimen... (Source: Health News from Medical News Today)

FDA Approves Five-Day Dosing Regimen For Dacogen(R) (decitabine) For Injection, Offering A New Outpatient Dosing Option For Myelodysplastic Syndromes

Lymphoma / Leukemia News From Medical News Today — Sat, 13 Mar 2010 09:00:00 +0100

Current approaches to the management of pediatric hodgkin lymphoma.

Paediatric Drugs — Sat, 13 Mar 2010 00:40:18 +0100

Authors: Freed J, Kelly KM Hodgkin lymphoma is one of the few cancers that affect both adults and children. Cure rates for Hodgkin lymphoma remain among the best for pediatric cancers. However, cure is often associated with significant delayed effects of therapy, including an elevated risk for second malignancies, cardiotoxicity, pulmonary toxicity, and gonadal and non-gonadal endocrine dysfunction. Therefore, the aim of current treatment strategies is to further improve outcomes while minimizing therapy-related complications. At diagnosis, patients are classified into risk groups based on disease stage, and the presence of clinical, biologic, and serologic risk factors. In general, the most recent trials have intensified therapy in those patients with high-risk disease to improve dise...

Whole-body MRI for staging Hodgkin lymphoma in a pregnant patient

American Journal of Hematology — Sat, 13 Mar 2010 00:00:00 +0100

No abstract. (Source: American Journal of Hematology)

Identification of native Bacillus thuringiensis strain from South India having specific cytocidal activity against cancer cells

Journal of Applied Microbiology — Sat, 13 Mar 2010 00:00:00 +0100

Conclusions: Our observations imply that B. thuringiensis LDC-391 is different from the already reported parasporin producers, as it is showing variation in the target specificity.Significance and Impact of the Study: Characterizing these proteins can pave the way to alleviate problems associated with neoplastic transformation and cancer progression. (Source: Journal of Applied Microbiology)

Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006

Journal of Antimicrobial Chemotherapy — Fri, 12 Mar 2010 16:27:28 +0100

Conclusions Compared with 1995–2001, IFI-related mortality decreased and OS in patients with IFI increased significantly in recent years. Improved OS was associated with controlled haematological disease, certainty of IFI diagnosis (possible), younger age, time period 2002–06 and the use of novel antifungals. (Source: Journal of Antimicrobial Chemotherapy)

Seaweed extract may hold promise for non-Hodgkin's lymphoma treatment

ScienceDaily Headlines — Fri, 12 Mar 2010 16:00:00 +0100

Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research. Seaweeds containing fucoidan, a sulfated polysaccharide similar to heparin in chemical structure, have been reported to have anti-tumor activity in mice and some cell lines. (Source: ScienceDaily Headlines)

Primary Hodgkin's disease of the thymus

Respiratory Medicine CME — Fri, 12 Mar 2010 15:35:02 +0100

We report a 25-year-old man referred to us because of chest pain and irritating cough since 2 months. Physical examination was normal and no lymph nodes were palpable. Chest radiography showed an anterior mediastinal mass. Computed tomography (CT) examination of the chest revealed a homogeneous tissular mass occupying the anterior mediastinum in its upper and medium stage, extending to the infundibulum without lymph node enlargement. Thymectomy and wedge were performed via a median sternotomy. Pathologic diagnosis was nodular sclerosis Hodgkin's disease of the thymus. The patient received 6 cycles of ABVD (Adriamycin [doxorubicin], bleomycin, vinblastin and dacarbazine) and mediastinal radiotherapy. Currently, tow years after diagnosis, he is well and free of disease.Primary thymic Hodgkin...

Denileukin diftitox improved overall response rate in cutaneous T-cell lymphoma

HemOncToday.com — Fri, 12 Mar 2010 10:11:00 +0100

(Source: HemOncToday.com)

Seaweed May Help Treat Lymphoma

MedicineNet Cancer General — Fri, 12 Mar 2010 07:00:00 +0100

Title: Seaweed May Help Treat LymphomaCategory: Health NewsCreated: 3/11/2010 10:10:00 AMLast Editorial Review: 3/12/2010 (Source: MedicineNet Cancer General)

Imaging of head and neck neoplasms in children

Pediatric Radiology — Fri, 12 Mar 2010 06:47:44 +0100

Abstract The characteristic imaging appearance for a variety of common and/or important pediatric head and neck tumors will be described in this review. These include benign masses such as hemangioma, teratoma, nerve sheath tumors, juvenile nasopharyngeal angiofibroma and malignant masses such as rhabdomyosarcoma, lymphoma, carcinoma and retinoblastoma. This review focuses primarily on soft tissue tumors. Content Type Journal ArticleCategory ReviewDOI 10.1007/s00247-009-1526-9Authors Caroline D. Robson, Children’s Hospital Boston Department of Radiology 300 Longwood Avenue Boston MA 02115-5737 USA Journal Pediatric RadiologyOnline ISSN 1432-1998Print ISSN 0301-0449 Journal Volume Volume 40 Journal Issue Volume 40, Number 4 / April, 2010 (Source: Pediat...

Review of radiolabelled immunotherapy (90Y ibritumomab tiuxetan - Zevalin® or 131I tositumomab - Bexxar®) as either consolidation therapy after remission induction in previously untreated patients or in patients with relapsed/refractory follicular lymphom

NeLM - Drug Class Focused Reviews — Fri, 12 Mar 2010 00:00:00 +0100

Source: No information given Area: Evidence > Drug Class Focused Reviews This LCNDG review acts as an update to the review published in 2004 (appendix 3) Lymphomas are cancers of the lymphatic system and non-Hodgkin's lymphomas are a heterogeneous group, which vary considerably in their prognosis and management. The majority of non-Hodgkin's lymphomas (80-85%) derive from the B-cell lymphocytes, the rest originate from T-cells or undifferentiated cells. Follicular lymphoma is a common histological type of NHL, originating from B-lymphocytes. Both 131I tositumomab (Bexxar®) and 90Y ibritumomab tiuxetan (Zevalin®) are murine monoclonal antibodies directed against the CD20 antigen expressed on the surface of normal and malignant B-lymphocytes. Radiolabelled ibritumomab is license...

Hairy cell leukaemia-variant and splenic red pulp lymphoma: a single entity?

British Journal of Haematology — Fri, 12 Mar 2010 00:00:00 +0100

(Source: British Journal of Haematology)

Chromosome 9p24 abnormalities: prevalence, description of novel JAK2 translocations, JAK2V617F mutation analysis and clinicopathologic correlates

European Journal of Haematology — Fri, 12 Mar 2010 00:00:00 +0100

Conclusions: Chromosome 9p24 abnormalities are rare and do not always involve JAK2. The subset with JAK2 translocations are usually associated with MPN and harbor JAK2V617F, suggesting a cause-effect relationship. The current study also describes five novel translocations involving JAK2. (Source: European Journal of Haematology)

Epidemiology and outcome of Rhodotorula infection in haematological patients

Mycoses — Fri, 12 Mar 2010 00:00:00 +0100

Rhodotorula spp. are emergent opportunistic pathogens, particularly in haematological patients. However, no systematic review of this infection has been undertaken in this high-risk patient group. The aim of this study was to review all reported cases of Rhodotorula infection to determine the epidemiology and outcome of this infection in this high-risk population. The 29 reported cases were fungaemias. The most common underlying haematological disorder was the presence of acute leukaemia (65.5%). Rhodotorula mucilaginosa was the species found more frequently (79.3%). Most cases (58.6%) had several risk factors ([ge]3) simultaneously. The most common predisposing factors were the presence of central venous catheter (CVC, 100%) and neutropenia (62.1%). A substantial number of patients (81.5%...

Review of radiolabelled immunotherapy (90Y ibritumomab tiuxetan - Zevalin® or 131I tositumomab - Bexxar®) as either consolidation therapy after remission induction in previously untreated patients or in patients with relapsed/refractory follicular lymphom

NeLM - Drug Class Focused Reviews — Fri, 12 Mar 2010 00:00:00 +0100

Review of radiolabelled immunotherapy (90Y ibritumomab tiuxetan - Zevalin(r) or 131I tositumomab - Bexxar(r)) in patients with follicular lymphoma

NeLM - Drug Class Focused Reviews — Fri, 12 Mar 2010 00:00:00 +0100

Source: London New Drugs Group Area: Evidence > Drug Class Focused Reviews This LCNDG review acts as an update to the review published in 2004 (appendix 3) Lymphomas are cancers of the lymphatic system and non-Hodgkin's lymphomas are a heterogeneous group, which vary considerably in their prognosis and management. The majority of non-Hodgkin's lymphomas (80-85%) derive from the B-cell lymphocytes, the rest originate from T-cells or undifferentiated cells. Follicular lymphoma is a common histological type of NHL, originating from B-lymphocytes. Both 131I tositumomab (Bexxar®) and 90Y ibritumomab tiuxetan (Zevalin®) are murine monoclonal antibodies directed against the CD20 antigen expressed on the surface of normal and malignant B-lymphocytes. Radiolabelled ibritumomab is li...

Primary diffuse large B-cell central nervous system lymphoma presenting as an acute space-occupying subdural mass.

Journal of Neurosurgery — Fri, 12 Mar 2010 00:00:00 +0100

Authors: Sacho RH, Kogels M, Plessis DD, Jowitt S, Josan VA Primary dural lymphomas are very rare tumors-usually low-grade B-cell lymphomas of mucosa-associated lymphoid tissue type or marginal zone B-cell lymphomas. Primary dural involvement by diffuse large B-cell lymphoma is extremely rare, with only a few cases reported in the literature. The authors present an unusual case of primary dural involvement by a high-grade diffuse large B-cell lymphoma that presented as an acute subdural space-occupying mass and required emergency neurosurgical intervention. PMID: 20225921 [PubMed - as supplied by publisher] (Source: Journal of Neurosurgery)

[Familial splenomegaly as a first clinical sign of autoimmune lymphoproliferative syndrome.]

Anales de Pediatria — Fri, 12 Mar 2010 00:00:00 +0100

Authors: Bilbao Aburto A, Arana Aguirre N, García Martínez JM, Astigarraga Aguirre I, Allende LM BACKGROUND: The autoimmune lymphoproliferative syndrome (ALPS) is caused by genetic defect in lymphocyte apoptosis. Chronic lymphadenopathy and splenomegaly are the consequence of lymphoproliferation. The diagnosis is based on the assessment of the defective lymphocyte apoptosis and the identification of lymphocyte T subset that are double negative (CD4-CD8-). The susceptibility to lymphoma and autoimmune diseases, mainly blood cytopenias is increased. METHODS: We studied a 14 year-old boy with chronic splenomegaly and familial history of splenomegaly and lymphadenopathy. T lymphocyte phenotypes, and molecular defect of TNFRSF6 gene were studied in the child, his sister and his fa...

Psoriasis Is Associated With an Increased Risk of Cancer

Medscape Hematology-Oncology Headlines — Thu, 11 Mar 2010 17:31:27 +0100

Psoriasis is associated with a significantly greater risk of malignancy, including skin and prostate cancer and non-Hodgkin's lymphoma, according to new research presented here at the 68th annual meeting of the American Academy of Dermatology (AAD 2010). Reuters Health Information (Source: Medscape Hematology-Oncology Headlines)

Challenging the adult T-cell leukemia/lymphoma (ATL) stem cell concept based on limiting dilution transplantation assay

Blood — Thu, 11 Mar 2010 17:02:03 +0100

(Source: Blood)

Response: Estimating frequency of cancer stem cells in a mouse model of adult T-cell leukemia/lymphoma

Blood — Thu, 11 Mar 2010 17:02:03 +0100

(Source: Blood)

New Test Identifies Hodgkin's Lymphoma Poor Prognosis, Could Change "Landscape of Treatment"

Medscape Pathology Headlines — Thu, 11 Mar 2010 15:41:55 +0100

A new test that identifies patients with Hodgkin's lymphoma who respond poorly to treatment could revolutionize this field, says expert. Medscape Medical News (Source: Medscape Pathology Headlines)

Cancer patients benefit from advance in diagnosis

CBC | Health — Thu, 11 Mar 2010 14:19:25 +0100

An international team of cancer researchers has found a way to predict which Hodgkin's lymphoma patients won't respond well to therapies, opening the door to using a less aggressive regimen on those more likely to be cured. (Source: CBC | Health)

CD68+ cells associated with primary treatment failure, poor survival in Hodgkin’s lymphoma

HemOncToday.com — Thu, 11 Mar 2010 13:26:00 +0100

(Source: HemOncToday.com)

Seaweed Extract May Hold Promise For Non-Hodgkin's Lymphoma Treatment

Lymphoma / Leukemia News From Medical News Today — Thu, 11 Mar 2010 11:00:00 +0100

Seaweed Extract May Hold Promise For Non-Hodgkin's Lymphoma Treatment

Health News from Medical News Today — Thu, 11 Mar 2010 11:00:00 +0100

Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research: From the Laboratory to the Clinic, held here March 7-10, 2010. Lymphoma is a cancer of the immune system and is classified into Hodgkin's and non-Hodgkin's types, which are then further classified into B-cell and T-cell groups. "Some forms of B-cell lymphoma are especially resistant to standard treatment and thus new therapies are needed," said Mohammad Irhimeh, Ph.D... (Source: Health News from Medical News Today)

Surgical treatment of primary tracheobronchial malignant tumors

The Chinese-German Journal of Clinical Oncology — Thu, 11 Mar 2010 04:14:43 +0100

Conclusion Surgical resection is the most effective treatment for primary tracheobronchial malignant tumors. The selection of operation modes should be individualized according to patients’ condition. Both complete resection and safety should be taken into consideration simultaneously. Content Type Journal ArticleDOI 10.1007/s10330-009-0182-8Authors Hailong Wang, Guilin Medical College Department of Cardiothoracic Surgery, Affiliated Hospital Guilin 541001 ChinaZhenzong Du, Guilin Medical College Department of Cardiothoracic Surgery, Affiliated Hospital Guilin 541001 ChinaHua Ren, Peking Union Medical College Department of Cardiothoracic Surgery, Peking Union Medical College Hospital Beijing 100730 ChinaChaoji Zhang, Peking Union Medical College Department of Card...

Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205+ dendritic cells

Cancer Immunology, Immunotherapy — Thu, 11 Mar 2010 02:38:34 +0100

Abstract Two major distinct subsets of dendritic cells (DCs) are arranged to regulate our immune responses in vivo; 33D1+ and DEC-205+ DCs. Using anti-33D1-specific monoclonal antibody, 33D1+ DCs were successfully depleted from C57BL/6 mice. When 33D1+ DC-depleted mice were stimulated with LPS, serum IL-12, but not IL-10 secretion that may be mediated by the remaining DEC-205+ DCs was markedly enhanced, which may induce Th1 dominancy upon TLR signaling. The 33D1+ DC-depleted mice, implanted with syngeneic Hepa1-6 hepatoma or B16-F10 melanoma cells into the dermis, showed apparent inhibition of already established tumor growth in vivo when they were subcutaneously (sc) injected once or twice with LPS after tumor implantation. Moreover, the development of lung metastasis of B16-...

Study predicts treatment response in Hodgkin's patients

CTV Health — Thu, 11 Mar 2010 02:32:56 +0100

Primary large cell neuroendocrine carcinoma of the vagina: Cytomorphology of previously unreported case

Diagnostic Cytopathology — Thu, 11 Mar 2010 00:00:00 +0100

In this report, we describe a case of LCNEC of the vagina, which is believed to be the first case to date in the English literature. The patient is a 53-year old gravida 3, para 2, African-American woman who had a 4 month history of severe pelvic pain and difficulty voiding and was found to have a firm plate-like mass on the anterior vaginal wall. Thin prep of vaginal swap was interpreted as atypical glandular cells; however, the biopsies showed a large cell neuroendocrine carcinoma which was confirmed by diffuse strong immunoreactivity to AE1/3, CAM5.2, CK7, and CD56 in the tumor cells. Subsequent clinical workup showed that the patient also had numerous metastatic nodules in the bilateral lungs and a vaginal-urethral fistula caused by the tumor. The patient underwent palliative radiation...

Case review: Treatment for lymph node tuberculosis

NeLM - News — Thu, 11 Mar 2010 00:00:00 +0100

Source: BMJ Area: News The British Medical Journal has featured a review of lymph node tuberculosis. The authors explain that the diagnosis of lymph node tuberculosis and lymphoma are often confused, and highlight three case reports in which patients were misdiagnosed with tuberculosis, and which therefore led to a delay in the diagnosis and treatment of lymphoma. (Source: NeLM - News)

Micronodular T-cell/histiocyte-rich B-cell lymphoma of the spleen in a case of small lymphocytic lymphoma: A Richter's transformation.

Upsala Journal of Medical Sciences — Thu, 11 Mar 2010 00:00:00 +0100

Authors: Türköz HK, Polat N, Akin I, Ozcan D Abstract A case of micronodular T-cell/histiocyte-rich B-cell lymphoma of the spleen who had a prior diagnosis of small lymphocytic lymphoma is presented. Micronodular T-cell/histiocyte-rich B-cell lymphoma of the spleen was first described in 2003, and very few cases have been reported since then. This is the first reported case supervening in a patient with pre-existing chronic lymphocytic lymphoma. We review its clinical, pathologic, and immunohistochemical features and the difficulties we encountered during diagnosis. PMID: 20218944 [PubMed - as supplied by publisher] (Source: Upsala Journal of Medical Sciences)

Isolated Limb Perfusion with Melphalan for the Treatment of Intractable Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.

Acta Haematologica — Thu, 11 Mar 2010 00:00:00 +0100

Authors: Kobold S, Killic N, Lütkens T, Bokemeyer C, Fiedler W PMID: 20224270 [PubMed - as supplied by publisher] (Source: Acta Haematologica)

mir-17-92, a cluster of miRNAs in the midst of the cancer network.

The International Journal of Biochemistry and Cell Biology — Thu, 11 Mar 2010 00:00:00 +0100

Authors: Olive V, Jiang I, He L MicroRNAs (miRNAs) are an abundant class of small non-coding RNAs (ncRNAs) that function to regulate gene expression at the post-transcriptional level. Although their functions were originally described during normal development, miRNAs have emerged as integral components of the oncogenic and tumor suppressor network, regulating nearly all cellular processes altered during tumor formation. In particular, mir-17-92, a miRNA polycistron also known as oncomir-1, is among the most potent oncogenic miRNAs. Genomic amplification and elevated expression of mir-17-92 were both found in several human B-cell lymphomas, and its enforced expression exhibits strong tumorigenic activity in multiple mouse tumor models. mir-17-92 carries out pleiotropic functions during...

Hepatosplenic αβ T cell lymphoma

International Journal of Clinical Oncology — Wed, 10 Mar 2010 16:13:26 +0100

Abstract A 32-year-old male with chronic hepatitis B was admitted to a hospital with cellulitis in the right leg in September 2006. Pancytopenia, hepatosplenomegaly, and systemic superficial lymph node swelling were noted, and he was referred to our hospital. He developed fever and liver dysfunction in June 2007 and underwent a splenectomy. His pancytopenia subsequently improved. A pathologic diagnosis of hepatosplenic αβ T cell lymphoma was made by examining spleen tissue and biopsy specimens of the liver and mesenteric lymph node. He had stage IVB disease because neoplastic T cells were noted in the bone marrow. The response of the lymphoma to conventional chemotherapy including the CHOP (cyclophosphamide, adriamycin, vincristine, prednisolone) and DeVIC (dexamethasone...

Wide-mouthed Sacculation of the Esophagus: A Cause of Dysphagia after Radiation Therapy

Dysphagia — Wed, 10 Mar 2010 16:10:01 +0100

We describe a patient who presented with dysphagia after radiation therapy for Hodgkin’s lymphoma secondary to wide-mouthed sacculation of the upper esophagus on barium esophagography, most likely resulting from localized radiation necrosis of the muscular layer of the esophageal wall. Despite its rarity, radiologists should be aware of this finding as a potential cause of dysphagia after radiation therapy to the neck or chest. Unlike radiation strictures, radiation-induced sacculation of the esophagus probably can be managed conservatively without need for endoscopic dilatation procedures. Content Type Journal ArticleCategory Case ReportDOI 10.1007/s00455-010-9274-4Authors Xin Wu, Hospital of the University of Pennsylvania Department of Radiology 3400 Spruce Street Philadelph...

18F-FDG PET/CT bone/bone marrow findings in Hodgkin’s lymphoma may circumvent the use of bone marrow trephine biopsy at diagnosis staging

European Journal of Nuclear Medicine and Molecular Imaging — Wed, 10 Mar 2010 16:09:59 +0100

Conclusion 18F-FDG PET/CT highly improves sensitivity for diagnosis of bone/bone marrow lesions in HL compared to conventional staging. Content Type Journal ArticleCategory Original ArticleDOI 10.1007/s00259-009-1377-5Authors Gerard Moulin-Romsee, Université Paris 7 Service de Médicine Nucléaire, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris 1, avenue Claude Vellefaux 75475 Paris cedex 10 FranceElif Hindié, Université Paris 7 Service de Médicine Nucléaire, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris 1, avenue Claude Vellefaux 75475 Paris cedex 10 FranceXavier Cuenca, Hôpital Saint-Louis Haemato-Oncology Paris FrancePauline Brice, Hôpital Saint-Louis Haemato-Oncology Paris FranceDidier Decaudin, Institut Curie Haematology Pari...

NK/T cell non-Hodgkin lymphoma in a HIV-positive patient

Journal of Hematopathology — Wed, 10 Mar 2010 16:08:50 +0100

Abstract NK/T lymphomas have rarely been reported in HIV/AIDS patients. Here we report a case of a 37-year-old woman, with AIDS and a recent diagnosis of Kaposi sarcoma in a mesenteric lymph node, who presented with extra-ocular nerve palsies and gastrointestinal bleeding. A small intestine resection specimen revealed an extra-nodal NK/T cell lymphoma, nasal type. The unique presentation of this rare and aggressive lymphoma in the setting of AIDS and Kaposi sarcoma underscores the importance of maintaining a broad differential diagnosis when evaluating a malignant neoplasm from a HIV-positive patient. Content Type Journal ArticleCategory Case ReportDOI 10.1007/s12308-010-0057-5Authors Nicole C. Panarelli, Weill Cornell Medical College Department of Pathology and Labor...

Cytotoxic peripheral T cell lymphoma arising in a patient with nodular lymphocyte predominant Hodgkin lymphoma: a case report

Journal of Hematopathology — Wed, 10 Mar 2010 16:08:49 +0100

Abstract In this paper, we describe a case of nodular lymphocyte predominant Hodgkin lymphoma with the subsequent development of a peripheral T cell lymphoma. This case is unusual in that the sheets of atypical and small to intermediate-sized T cells in the diffuse component were CD8 positive and expressed cytotoxic proteins. The diagnosis of peripheral T cell lymphoma was supported by the demonstration of a clonal T cell receptor beta chain gene rearrangement by Southern blot analysis. Peripheral T cell lymphoma with a cytotoxic phenotype is a rare entity with an aggressive clinical behavior. As such, this report emphasizes the need to consider a diagnosis of coexisting peripheral T cell lymphoma in cases of nodular lymphocyte predominant Hodgkin lymphoma with atypical fe...

2010 Recipient Of Minority Scholar Award Will Conduct Clinical Research On Leukemia

Health News from Medical News Today — Wed, 10 Mar 2010 16:00:00 +0100

Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year. The award, designed to help increase the number of underrepresented minority scholars in the field of hematology, is the result of a partnership between the American Society of Hematology (ASH) and the Harold Amos Medical Faculty Development Program (AMFDP) of the Robert Wood Johnson Foundation. It provides four years of support, including an annual stipend of up to $75,000 and an annual grant of $30,000 to support research activities... (Source: Health News from Medical News Today)

2010 Recipient Of Minority Scholar Award Will Conduct Clinical Research On Leukemia

Cancer / Oncology News From Medical News Today — Wed, 10 Mar 2010 16:00:00 +0100

Alison Walker, MD, has been selected to receive the ASH-AMFDP Award, and will begin her research in acute myeloid leukemia in July of this year... (Source: Cancer / Oncology News From Medical News Today)

Concomitant statin use does not impair the clinical outcome of patients with diffuse large B cell lymphoma treated with rituximab-CHOP

Annals of Hematology — Wed, 10 Mar 2010 15:33:39 +0100

Abstract Preclinical data indicated a detrimental effect of statins on the anti-lymphoma activity of rituximab. We evaluated the impact of concomitant statin medication on the response and survival of patients with diffuse large B cell lymphoma (DLBCL) receiving rituximab–cyclophosphamide, doxorubicin, vincristine, prednisone (R-CHOP) as first-line therapy. Medical histories of patients with DLBCL who were treated with R-CHOP as first-line therapy were assessed for concomitant statin use, response after completion of chemotherapy, event-free survival (EFS), and overall survival (OS). Furthermore, 2-[18F]fluor-2-deoxyglucose (FDG)-PET/CT results after completion of first-line therapy were compared between the groups. Overall, 145 patients with DLBCL treated with R-CHOP fro...

Non-Hodgkins Lymphoma in the Elderly

Drugs — Wed, 10 Mar 2010 15:24:13 +0100

(Source: Drugs)

Risk of non-Hodgkin lymphoma and nitrate and nitrite from the diet in Connecticut women

Cancer Causes and Control — Wed, 10 Mar 2010 13:22:28 +0100

Abstract It has been estimated that 65,980 individuals were diagnosed with non-Hodgkin lymphoma (NHL) and 19,500 died from NHL in the United States in 2009. Although established risk factors such as immunodeficiency and viral infections may be responsible for a portion of the cases, the majority of NHL cases remain unexplained. Dietary nitrate and nitrite intake are exposures of particular interest for NHL risk as they are precursors in the endogenous formation of N-nitroso compounds, which cause lymphomas in animal studies. We investigated NHL risk overall and by histologic type in relation to dietary nitrate and nitrite intake in a population-based case–control study of 1,304 women in Connecticut. Nitrate and nitrite intake were assessed using a 120-item food frequency...

Seaweed extract may hold promise for non-Hodgkin's lymphoma treatment

EurekAlert! - Cancer — Wed, 10 Mar 2010 05:00:00 +0100

(American Association for Cancer Research) Seaweed extract may eventually emerge as a lymphoma treatment, according to laboratory research presented at the second AACR Dead Sea International Conference on Advances in Cancer Research. (Source: EurekAlert! - Cancer)

Phase III trial of denileukin diftitox for patients with cutaneous T-cell lymphoma shows benefit

NeLM - News — Wed, 10 Mar 2010 00:00:00 +0100

Source: JCO Area: News According to research published early online in the Journal of Clinical Oncology, denileukin diftitox (DD) produces a statistically significant and durable effect on overall response rate (ORR) and progression-free survival (PFS) in patients with early- and late-stage cutaneous T-cell lymphoma (CTCL). Researchers evaluated the efficacy and safety of two doses of DD, a recombinant fusion protein targeting IL-2 receptor-expressing malignant T lymphocytes, in patients with biopsy-confirmed stage IA to III, CD25 assay-positive CTCL, including the mycosis fungoides and Sézary syndrome forms of the disease, who had received up to three prior therapies. The primary end point was ORR. Patients were randomised to receive DD 9 mcg/kg/day (n = 45), DD 18...

Macrophages' Association With Survival in Hodgkin's Studied

Modern Medicine — Wed, 10 Mar 2010 00:00:00 +0100

In patients with classic Hodgkin's lymphoma, having a higher number of tumor-associated macrophages is linked to shortened survival, a finding that may assist in risk stratification, according to research published in the March 11 New England Journal of Medicine. (Source: Modern Medicine)

Cutaneous intravascular anaplastic large cell lymphoma

Journal of Cutaneous Pathology — Wed, 10 Mar 2010 00:00:00 +0100

Intravascular lymphoma (IL) is a rare variant of non-Hodgkin lymphoma with a predilection for skin. Most reported cases are large B cell lymphomas. Intravascular anaplastic large cell lymphoma (IALCL) is extremely rare. Retrospective analysis of a case of cutaneous IALCL was performed. Hematoxylin and eosin stained sections and immunohistochemical staining results were analyzed. The patient was a 47-year-old woman who had developed multiple erythematous patches and plaques on her back. The lesions responded well to CHOP (cyclophosphamide, hydroxydoxorubicin, oncovin, prednisone) chemotherapy, but relapsed shortly after therapy. The patient was surviving with the disease for eight years but was ultimately lost to follow up. Histopathologically, the neoplasm evolved from IL to extravascular ...

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

New England Journal of Medicine — Wed, 10 Mar 2010 00:00:00 +0100

In this study, gene profiling and immunohistochemical analysis were used to find such a marker. A strong association was found between a poor outcome of treatment and an increased number of CD68+ cells in the microenvironment of Reed-Sternberg cells. CD68, a marker of macrophages, outperformed the conventional International Prognostic Score and is available for immunohistochemical staining of diagnostic samples of Hodgkin's lymphoma. (Source: New England Journal of Medicine)

Imaging in Early-Stage Hodgkin's Lymphoma

New England Journal of Medicine — Wed, 10 Mar 2010 00:00:00 +0100

To the Editor: Data on exposure to low-dose ionizing radiation from medical imaging procedures indicate that medical imaging can potentially ... (Source: New England Journal of Medicine)

Severe hypogammaglobulinemia persisting for 6 years after treatment with rituximab combined chemotherapy due to arrest of B lymphocyte differentiation together with alteration of T lymphocyte homeostasis.

International Journal of Hematology — Wed, 10 Mar 2010 00:00:00 +0100

We report a case of prolonged severe hypogammaglobulinemia after rituximab combined chemotherapy for follicular lymphoma. Although the patient's globulin level was within the normal limits before treatment, the level of IgG dropped below 100 mg/dL, and both IgA and IgM became undetectable after treatment, and the levels have shown no changes for 6 years despite recovery of peripheral B cell counts. Phenotypic analysis of B cells revealed a reduction of class-switched CD27+IgM-IgD- memory B cells below 0.5% and overexpression of CD95. On the other hand, we observed the predominance of memory T cell subsets in both of CD4+ and CD8+ T cells as the result of reduction of naïve T cells. These increased memory T cells overexpressed activation markers such as CD69, CD95, and HLA-DR. Furtherm...

A case of HIV-associated lymphoproliferative disease that was successfully treated with highly active antiretroviral therapy.

International Journal of Hematology — Wed, 10 Mar 2010 00:00:00 +0100

We report a case of a 41-year-old male with human immunodeficiency virus (HIV)-associated lymphoproliferative disease (LPD) who was successfully treated with highly active antiretroviral therapy (HAART). He presented with epigastralgia, and an upper endoscopic examination revealed submucosal tumors and ulcerations in his stomach. Histopathologic examination of a biopsy specimen resulted in a diagnosis of diffuse large B-cell lymphoma. He also showed systemic lymphadenopathy; whereas, a concurrent inguinal lymph node biopsy produced a diagnosis of follicular hyperplasia. He was treated with CHOP chemotherapy but the response was poor. He demonstrated several immunological abnormalities, such as eosinophilia and bone marrow insufficiency, and was suspected to be in an immunocompromised state...

Splenic diffuse red pulp small B-cell lymphoma: revision of a series of cases reveals characteristic clinico-pathological features.

Haematologica — Wed, 10 Mar 2010 00:00:00 +0100

Conclusions: Our data suggest that SDRPSBCL is a distinct entity with morphological and immunophenotypic features that differ from those of other splenic lymphomas. PMID: 20220064 [PubMed - as supplied by publisher] (Source: Haematologica)

Identification of a panel of ten cell surface protein antigens associated with immunotargeting of leukemias and lymphomas by peripheral blood {gamma}{delta}T cells.

Haematologica — Wed, 10 Mar 2010 00:00:00 +0100

Conclusions Our results suggest that hematopoietic tumors display a highly variable repertoire of surface proteins that can impact on VgammaVdelta cell-mediated immunotargeting. The prognostic value of the proposed markers can now be evaluated in upcoming VgammaVdelta T cell-based lymphoma/ leukaemia clinical trials. PMID: 20220060 [PubMed - as supplied by publisher] (Source: Haematologica)

Evaluation of the (R)VAD+C regimen for the treatment of newly diagnosed Mantle Cell Lymphoma. Combined results of two prospective phase II trials from the French GOELAMS group.

Haematologica — Wed, 10 Mar 2010 00:00:00 +0100

CONCLUSION The (R)VAD+C is an effective regimen with very low toxicity. In addition to the MIPI score, Ki67 expression provides additional independent prognostic information for the prediction of OS. PMID: 20220059 [PubMed - as supplied by publisher] (Source: Haematologica)

PRL-2 increases Epo and IL-3 responses in hematopoietic cells.

Blood Cells, Molecules & Diseases — Wed, 10 Mar 2010 00:00:00 +0100

Authors: Akiyama S, Dhavan D, Yi T Dual specificity protein tyrosine phosphatase PRL-2 is overexpressed in pediatric acute myeloid leukemia (AML) and is located at human chromosome 1p35, a region often rearranged or amplified in malignant lymphoma and B-cell chronic lymphocytic leukemia (B-CLL). Little is known of the significance of PRL-2 expression in hematopoietic malignancies. Herein we demonstrated that ectopic expression of PRL-2 in murine pre-B-cell line Baf3ER and mouse bone marrow cells induced key features associated with malignant progression and metastasis. PRL-2-transfected Baf3ER cells had augmented growth responses to hematopoietic growth factors Epo or IL-3 with shortened cell cycle, reduced requirement (5x) for Epo in cell survival, increased cell migration (3x), reduc...

Molecular detection of host cytokine expression in

Indian Journal of Medical Microbiology — Tue, 09 Mar 2010 17:15:51 +0100

Hosseini M Eshagh, Oghalaie A, Habibi G, Nahvijoo A, Hosseini Z M, Tashakoripoor M, Mohammadi MIndian Journal of Medical Microbiology 2010 28(1):40-44Background: Helicobacter pylori (Hp) is a bacterium recognised as a main causative agent for the development of chronic active gastritis, peptic ulcer disease, gastric adenocarcinoma and primary gastric lymphoma. Objective: Determination of the levels of IFN-&#947; (pro-inflammatory) and IL-4 (anti inflammatory) cytokine expression as indicators of Th1 and Th2 immune responses in gastric cancer (GC) and non gastric cancer (Non GC) dyspeptic patients by gene specific RT-PCR. Materials and Methods: Biopsy specimens were collected from three groups of gastric cancer (GC=18), non ulcer dyspepsia (NUD = 38) and peptic ulcer patients (PU...

Role of reactive perivascular lymphocytic infiltrate in primary central nervous system lymphoma

Journal of Postgraduate Medicine — Tue, 09 Mar 2010 16:15:37 +0100

Bhagavathi SJournal of Postgraduate Medicine 2009 55(4):240-241 (Source: Journal of Postgraduate Medicine)

Primary central nervous system lymphoma: Prognostication as per international extranodal lymphoma study group score and reactive CD3 collar

Journal of Postgraduate Medicine — Tue, 09 Mar 2010 16:15:37 +0100

Conclusion : Approximately 90% (27 cases) were associated with poor prognostic factors in the present study according to the IELSG score. Perivascular reactive CD3 collar was seen in cases with low to intermediate IELSG score. A larger study is required to further validate that the presence of reactive perivascular CD3 collar is associated with good prognosis. This histological marker could be supplemented with IELSG score to stratify the patients of primary CNS lymphoma according to their aggressiveness. (Source: Journal of Postgraduate Medicine)

Cerebral Infratentorial Large B-Cell Lymphoma Presenting as Parkinsonism.

The Tohoku Journal of Experimental Medicine — Tue, 09 Mar 2010 11:04:05 +0100

Authors: Lin CM, Hong K Though rare, primary intracranial tumors can present with Parkinsonian symptoms, and diagnosis can be delayed unless there is a high index of suspicion. We herein present an 81-year-old man who was seen in our neurology clinic due to acute onset of unsteady gait and altered consciousness. Parkinsonism was initially diagnosed because of the typical manifestations. Levodopa was prescribed; however, there was a limited effect on his symptoms. Upon detail history and neurological examination, left sided hemiparesis was disclosed. Cerebral imaging studies revealed a solid mass over the right infratentorial para-midbrain area leading to reactive obstructive hydrocephalus. Work-up including chest and abdominal CT scanning, upper and lower GI endoscopy, and tumor marker...

Rituximab Plus Dose–Reduced Cyclophosphamide, Mitoxantrone, Vincristine, and Prednisolone Are Effective in Elderly Patients with Diffuse Large B-Cell Lymphoma of the Thyroid

Thyroid — Tue, 09 Mar 2010 05:52:12 +0100

Thyroid , Vol. 0, No. 0. (Source: Thyroid)

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy

British Journal of Haematology — Tue, 09 Mar 2010 00:00:00 +0100

(Source: British Journal of Haematology)

The AP-1 repressor protein, JDP2, potentiates hepatocellular carcinoma in mice

Molecular Cancer — Tue, 09 Mar 2010 00:00:00 +0100

Conclusions: This study suggests that JDP2 expression may play a critical role in liver cancer development by potentiating the compensatory proliferative response and increased inflammation in the DEN liver cancer model. (Source: Molecular Cancer)

Severe lactic acidosis, hypertriglyceridemia, and extensive axial skeleton involvement in a case of disseminated Burkitt's lymphoma.

International Journal of Hematology — Tue, 09 Mar 2010 00:00:00 +0100

Authors: Kulkarni K, Kaur S, Sibal A, Jerath N, Arya LS PMID: 20213117 [PubMed - as supplied by publisher] (Source: International Journal of Hematology)

Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial.

Clinical Cancer Research — Tue, 09 Mar 2010 00:00:00 +0100

CONCLUSIONS: CD22 represents an excellent target and anti-CD22 immunotoxins offer therapeutic promise in B-lineage hematologic malignancies of childhood. Clin Cancer Res; 16(6); 1894-903. PMID: 20215554 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)

Linkage of expression of chemokine receptors (CXCR3 and CCR4) and cytotoxic molecules in peripheral T cell lymphoma, not otherwise specified and ALK-negative anaplastic large cell lymphoma.

International Journal of Hematology — Tue, 09 Mar 2010 00:00:00 +0100

Authors: Asano N, Suzuki R, Ohshima K, Kagami Y, Ishida F, Yoshino T, Ogawa H, Morishima Y, Nakamura S Peripheral T cell lymphoma not otherwise specified (PTCL-N) and ALK-negative anaplastic large cell lymphoma (ALCL) are heterogeneous categories with poor diagnostic reproducibility. To clarify the biologic features of these categories, we investigated the expression of two chemokine receptors, type 1 (Th1/Tc1)-associated CXCR3 and type 2 (Th2/Tc2)-associated CCR4 in 110 PTCL-N and 35 ALK-negative ALCL cases, as well as the expression of cytotoxic molecules (CM). CXCR3 and CCR4 were expressed in 69 (63%) and 37 (34%) of PTCL-N, and in 12 (34%) and 6 (17%) of ALK-negative ALCL, respectively. In PTCL-N, type 1 pattern (CXCR3(+)CCR4(-)) was dominant (52%), whereas in ALK-negative ALCL, 54...

Cost Effectiveness of Positron Emission Tomography in Patients With Hodgkin's Lymphoma in Unconfirmed Complete Remission or Partial Remission After First-Line Therapy [Hematologic Malignancies]

Journal of Clinical Oncology — Mon, 08 Mar 2010 23:01:30 +0100

Conclusion FDG-PET demonstrated 95.9% accuracy in restaging for patients with HL with CRu/PR after first-line therapy. Given the observed probabilities, FDG-PET is highly cost effective and would reduce costs for the public health care program in Brazil. (Source: Journal of Clinical Oncology)

October 2009 Archives Web Quiz Winner [Archives Web Quiz Winner]

Archives of Opthalmology — Mon, 08 Mar 2010 20:50:47 +0100

(Source: Archives of Opthalmology)

Endogenous Streptococcus agalactiae (Group B Streptococcus) Endophthalmitis as a Presenting Sign of Precursor T-Cell Lymphoblastic Leukemia [Research Letters]

Archives of Opthalmology — Mon, 08 Mar 2010 20:50:47 +0100

(Source: Archives of Opthalmology)

Primary Central Nervous System Lymphoma [Neurological Review]

Archives of Neurology — Mon, 08 Mar 2010 20:50:43 +0100

(Source: Archives of Neurology)

FDG-PET a Pivotal Imaging Modality for Diagnosis of Stroke-Onset Intravascular Lymphoma [Images in Neurology]

Archives of Neurology — Mon, 08 Mar 2010 20:50:43 +0100

(Source: Archives of Neurology)

Key Cause Of Chronic Leukemia Progression Identified By Study

Health News from Medical News Today — Mon, 08 Mar 2010 08:00:00 +0100

Researchers have discovered a key reason why a form of leukemia progresses from its more-treatable chronic phase to a life-threatening phase called blast crisis. The study, led by cancer researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James), indicates that chronic myeloid leukemia (CML) progresses when immature white blood cells lose a molecule called miR-328. Loss of the molecule traps the cells in a rapidly growing, immature state... (Source: Health News from Medical News Today)

Key Cause Of Chronic Leukemia Progression Identified By Study

Lymphoma / Leukemia News From Medical News Today — Mon, 08 Mar 2010 08:00:00 +0100

Tumors induced by Murine herpesvirus 60 or by cell line NB-78 derived from atumor induced by Murine herpesvirus 78 show presence of the inducing viruses.

Acta Virologica — Sun, 07 Mar 2010 03:29:31 +0100

Authors: Hrabovska Z, Chalupkova A, Mistrikova J Murine herpesviruses 60 and 78 (MHV-60, MHV-78), closely related to Mouse herpesvirus strain 68 (MHV-68), are oncogenic lymphotropic gammaherpesviruses, which may serve as models for study of human oncogenic gammaherpesviruses such as Epstein-Barr virus (EBV) and Kaposi's sarcoma-associated herpesvirus (KSHV). In this work, we attempted to detect an analog of the MHV-68 ORF73 gene in tumors induced in mice either directly by MHV-60 or indirectly by MHV-78 via inoculation of NB-78 cells derived from atumor induced by MHV-78. Besides the ORF73 gene, viral antigen and infectious virus were searched for. We succeeded in inducing lymphomas in mice by NB-78 cells and thus confirmed their transformed character. Importantly, we showed that the t...

Monosodium luminol upregulates the expression of Bcl-2 and VEGF in retrovirus-infected mice through downregulation of corresponding miRNAs.

Acta Virologica — Sun, 07 Mar 2010 03:29:31 +0100

In this study, we analyzed effect of GVT on the expression of B-cell lymphoma-2 protein (Bcl-2) and vascular endothelial growth factor (VEGF) in central nervous system (CNS) tissues of these animals. Our data showed that GVT treatment of ts1-infected mice significantly increased their expression of Bcl-2 and VEGF in brainstem compared with ts1-infected untreated mice. We also studied the expression of specific microRNAs (miRNAs) such as miRNA-15 and -16 (targeting Bcl-2), and miRNA-20 (targeting VEGF). We found that the expression of miRNAs inversely correlated with the upregulation of their target proteins in ts1-infected untreated as well as in GVT-treated-ts1-infected mice. The data showed that GVT treatment prevented ts1-induced ND at least in part by upregulating Bcl-2 and VEGF expres...

The role of radiology in head and neck tumours in children.

Cancer Imaging — Fri, 05 Mar 2010 16:08:03 +0100

We describe the imaging appearances of the common malignant tumours arising in the extracranial head and neck in children, focusing on lymphoma, rhabdomyosarcoma and nasopharyngeal carcinoma. The clinical presentation and radiological appearances of benign tumours in the head and neck in children may overlap with those seen in malignant disease. We describe the imaging appearances of juvenile angiofibroma, vascular abnormalities involving the extracranial head and neck and cervical teratomas. Advances in both imaging techniques and cancer staging systems, many of the latter aimed at avoiding over-treatment and treatment-related complications, will lead to an increasingly central role for imaging in childhood head and neck cancer. PMID: 20199940 [PubMed - in process] (Source: Cancer Ima...

Intracellular Succinylation of 8-Chloroadenosine and Its Effect on Fumarate Levels [Bioenergetics]

Journal of Biological Chemistry — Fri, 05 Mar 2010 14:37:12 +0100

8-Chloroadenosine (8-Cl-Ado) is a ribosyl nucleoside analog currently in phase I testing for the treatment of chronic lymphocytic leukemia (CLL). 8-Cl-Ado activity is dependent on adenosine kinase and requires intracellular accumulation of 8-Cl-Ado as mono-, di-, and tri-phosphates. In the current study with four mantle cell lymphoma cell lines, we report a new major metabolic pathway for 8-Cl-Ado intracellular metabolism, the formation of succinyl-8-chloro-adenosine (S-8-Cl-Ado) and its monophosphate (S-8-Cl-AMP). 8-Cl-AMP levels were highly associated with S-8-Cl-AMP levels and reached a steady-state prior to the secondary metabolites, 8-Cl-ATP and S-8-Cl-Ado. Consistent with fumarate as a required substrate for formation of succinyl-8-Cl-adenylate metabolites, the S-8-Cl-adenylate conce...

NICE Set To Recommend Rituximab For Relapsed Or Refractory Chronic Lymphocytic Leukaemia

Health News from Medical News Today — Fri, 05 Mar 2010 04:00:00 +0100

The National Institute for Health and Clinical Excellence (NICE) has today (4 March) issued final draft guidance recommending the drug rituximab(MabThera) as a treatment for certain patients with relapsed or refractory chronic lymphocytic leukaemia. This draft is now with consultees who have the opportunity to appeal against the proposed recommendations before final guidance is published later this year. Chronic lymphocytic leukaemia is a cancer of the white blood cells and is the most common form of leukaemia in the UK... (Source: Health News from Medical News Today)